BRD4 has emerged as a potential therapeutic target for a range of human diseases (Sun et al., 2024), including cancers (Zheng et al., 2022), gastrointestinal diseases (Ma et al., 2023), and cardiovascular diseases (Lin and Du, 2020). Here, BRD4 is linked to gastrointestinal disease.